Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines

This study has been terminated.
(Local authorities no longer require routine PMS studies;GSK does not believe the study would add meaningfully to the safety data already available for Synflorix)
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: January 7, 2010
Last updated: September 4, 2014
Last verified: September 2014

January 7, 2010
September 4, 2014
May 2010
July 2013   (final data collection date for primary outcome measure)
Occurrence of grade 3 unsolicited adverse events. [ Time Frame: Within 31 days (Day 0 - Day 30) after each vaccination. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01046097 on Archive Site
  • Occurrence of unsolicited adverse events. [ Time Frame: During 31 days (Day 0 - Day 30) follow-up period after each vaccination/vaccine dose. ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events. [ Time Frame: From the Dose 1 up to study end. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines
Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines
The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.
Not Provided
Phase 4
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Infections, Streptococcal
Biological: Synflorix™
Intramuscular administration of 1, 2, 3 doses or a booster dose according to local prescribing information
Experimental: Synflorix Group
Subjects receiving Synflorix™ according to local Prescribing Information.
Intervention: Biological: Synflorix™
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
  • Filipino male or female subjects whose age at the first vaccination with Synflorix is not lesser than 6 weeks of age.
  • For subjects who will receive vaccination on the second dose or third dose onwards, administration of the second dose or third dose of Synflorix as part of the post-marketing surveillance study should be according to the local Prescribing Information. Subjects who will complete their primary vaccination series either starting at first, second or third dose of Synflorix, booster dose will no longer be within the scope of the post-marketing surveillance for these subjects even if return for the booster dose and if they follow up.
  • Subjects will be enrolled in booster dose visit only if this is their first visit or first dose of Synflorix in the post-marketing surveillance. For subjects who will receive Synflorix as a booster dose to a primary vaccination series of a pneumococcal vaccine other than Synflorix, there should be an interval of at least 6 months from the last dose of primary vaccination.
  • Written, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s)/LAR of the child. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

  • Acute disease and/or fever at the time of vaccine administration.
  • Fever is defined as temperature >= 37.5°C on axillary, infrared or tympanic setting.
  • Subjects with a minor illness without fever may, be enrolled at the discretion of the investigator.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases.
  • Hypersensitivity to latex.
  • Any contraindications as stated in the Prescribing Information.
6 Weeks and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP